Artificial Intelligence in Pharmaceutical Manufacturing
Feature
Article
Pharmaceutical TechnologyPharmTech Sponsored eBooks-01-31-2024
Volume 2024 eBook
Issue 1
Pages: 12-15
FDA is anticipating how AI may advance manufacturing and improve supply chain security.
Cyborg hand holding a Medical icon and connection 3d rendering |©Production Perig - stock.adobe.com
Editor's Note: This article was previously published in Pharmaceutical Technology’s September 2023 issue.
Hollywood has long presented artificial intelligence (AI) as a futuristic concept far from reality, but technology has now eliminated the gap between science fiction and science fact. AI is here and here to stay; 50% of global healthcare companies plan to implement AI strategies by 2025 (1). For pharmaceutical manufacturers, AI has the potential to revolutionize process design and control, and thus bring benefits to patients and challenges to regulators.
Owing to its fictionalized past, the term AI can mean wildly different things to different people. FDA’s Center for Drug Evaluation and Research (CDER) describes AI rather inclusively as “a branch of computer science, statistics, and engineering that uses algorithms or models that exhibit behaviors such as learning, making decisions, and making predictions” (2). The National Academies of Sciences, Engineering, and Medicine issued a report on innovations in pharmaceutical manufacturing that highlighted AI’s potential role in the measurement, modeling, and control used for pharmaceutical manufacturing (3).
Read this article in the Regulating Innovation, Quality, and Risk eBook January 2024
About the author
Adam Fisher, PhD is Director of Science Staff and Immediate Office within the Office of Pharmaceutical Quality at the Center for Drug Evaluation and Research at FDA.
Article details
Pharmaceutical Technology/Pharmaceutical Technology Europe Regulating Innovation, Quality, and Risk eBook
Issue 1
January 2024
Pages: 12-15
.
Articles in this issue
Regulating Innovation, Quality, and Risk 2024
The Global Regulatory Village
Artificial Intelligence in Pharmaceutical Manufacturing
Master File Submission of Structures
Quality Quartets in Risk-Based Qualification:
ICH Q9: Attaining a Quality-Business Synergy through Quality Risk Management, ROI Analysis, and Highly Capable Facilities
Knowledge as the Currency of Managing Risk
Moderating Innovation to Equipoise Risk
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
